New research gives hope in the fight against pancreatic cancer

Prof Mariano Barbacid

writer

Prof Mariano Barbacid

Professor and Researcher AXA-CNIO of Molecular Oncology, National Center of Oncological Research CNIO

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is the third most common cause of death from cancer in the United States and the fifth most common in the United Kingdom. Deaths from PDAC outnumber those from breast cancer despite the significant difference in incidence rates.

Late diagnosis and ineffective treatments are the most important reasons for these bleak statistics.

PDAC is an aggressive and difficult malignancy to treat. Until now, the only chance for cure is the complete surgical removing of the tumor. Unfortunately, because PDAC is usually asymptomatic, by the time it is diagnosed 80% to 90% of patients have disease that is surgically incurable. PDAC thus remains one of the main biomedical challenges today due to its low survival rate – just 5% of patients are still alive five years after diagnosis.

However, in recent decades a number of studies have shed light on the molecular mechanisms responsible for the initiation and progression of PDAC. Our recent research has shown that progress toward a cure is possible.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Mark Yates

A/Prof Mark Yates

Dementia Chronic Disease – Practical Advice

Dr Julia Crawford

Dr Julia Crawford

Head and Neck Lumps

A/Prof Nicole Goh

A/Prof Nicole Goh

The NLCSP – Incidental Chest Findings – What Now? – A Focus on Interstitial Lung Abnormalities

A/Prof Martin MacDonald

A/Prof Martin MacDonald

Why are LAMAs Useful in Asthma Management

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Prof Mariano Barbacid

writer

Prof Mariano Barbacid

Professor and Researcher AXA-CNIO of Molecular Oncology, National Center of Oncological Research CNIO

Test your knowledge

Recent articles

Latest GP poll

AHPRA's new CEO says he is committed to improving how complaints are handled. How likely is this to succeed?

Likely to succeed

0%

Unlikely to succeed

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

We invite you to join the upcoming Healthed webcast where Prof Macrae speak on how GPs can suspect, assess and manage hereditary colorectal cancer risk.

Tuesday 2nd September, 7pm AEST

A/Prof Mark Yates

Director of Clinical Studies

We invite you to join the upcoming Healthed webcast where Prof Macrae speak on how GPs can suspect, assess and manage hereditary colorectal cancer risk.

Tuesday 2nd September, 7pm AEST